Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).Volker Heinemann, Sebastian Stintzing, Alexander Kiani et al.|Journal of Clinical Oncology|2013Cited by 102